NMN product shows increased endurance and new blood vessel growth in mice – ALIVE BY SCIENCE – Bioavailable NAD+ Boosters

NMN product shows increased endurance and new blood vessel growth in mice

This new research, published March 22 in Cell, identifies the key cellular mechanisms behind vascular aging and the key role it plays on muscle health.

Scientists at Harvard Medical School, Massachusetts Institute of Technology (MIT) and the University of New South Wales tested NMN, and MIB-626, which is a patent pending product developed by Metrobiotech that combines H2s with Nicotinamide Mononucleotide (NMN) to increase the effectiveness.

These researchers fed 400 mg/kg of NMN per day to 20-month-old mice, an age comparable to 70 years in people. After two months, the mice had increased muscular blood flow, enhanced physical performance and endurance and the old mice became as fit and strong as young mice.


We are as old as our arteries, the adage goes, so could reversing the aging of blood vessels hold the key to restoring youthful vitality?

In this study, the answer appears to be yes, at least in mice.

“We’ve discovered a way to reverse vascular aging by boosting the presence of naturally occurring molecules in the body that augment the physiological response to exercise,” said study senior investigator David Sinclair, Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for the Biology of Aging at Harvard Medical School.

As we grow old, we become weak and frail. A constellation of physiological changes—some subtle, some dramatic — precipitate this inevitable decline.

As we age, our tiniest blood vessels wither and die, causing reduced blood flow and compromises oxygenation of organs and tissues. Vascular aging is responsible for a myriad of disorders, such as cardiac and neurological conditions, muscle loss, impaired wound healing and overall frailty.

Scientists have known that loss of blood flow to organs and tissues leads to the build-up of toxins and low oxygen levels. Endothelial cells — which line blood vessels — are essential for the growth of new blood vessels that supply oxygen-rich and nutrient-loaded blood to organs and tissues.

But as these endothelial cells age, blood vessels atrophy, new blood vessels fail to form and blood flow to most parts of the body gradually diminishes. This dynamic is particularly striking in skeletal muscle, which is highly vascularized and depends on a robust blood supply to function.


Muscles begin to shrivel and grow weaker with age, a condition known as sarcopenia. The process can be slowed down with regular exercise, but even exercise becomes ineffective.

Sinclair and team wondered: What precisely curtails blood flow and precipitates this unavoidable decline? Why does even exercise lose its protective power to sustain muscle vitality? Is this process reversible?

In a series of experiments, the team found that reduced blood flow develops as endothelial cells start to lose a critical protein known as sirtuin1, or SIRT1. Supplementation with NMN boosts NAD+, stimulates SIRT1 and restores growth of endothelial cells.


After two months of receiving NMN, new blood vessels sprouted within the skeletal muscles of old mice. Capillary density increased and matched the capillary growth of young mice.

Remarkably, blood flow increased and the animals’ endurance (measured by how long they could run on a treadmill before before exhausting) was 56%-80% greater than that of untreated old mice: 1,400 feet compared to 780 feet.

Treated mice received the benefits of exercise just as mice half their age. In young animals, exercise spurs the creation of new blood vessels (neovascularization) and boosts muscle mass, which declines with age in both people and mice.

  • NMN restored the vascular system of old mice to that of young mice
  • Mice treated with NMN had a 1.6-fold increase in time and distance runs compared to untreated mice
  • In young, sedentary animals, NMN did not alter the capillarity or exercise capacity
  • In young animals, NMN + exercise resulted in 70% more capillaries than untreated, sedentary mice

NMN restored the blood-vessel- and muscle-boosting effects of a good treadmill run, basically “reversing vascular aging in the mice,” said study co-leader, David Sinclair of Harvard Medical School.

With exercise, the effect is even more dramatic: 32-month-old mice (equivalent to a 90-year-old human) were able to run on average TWICE as far as untreated mice.

The benefits of exercise diminish with time as decreased blood flow and muscle deterioration prevents adequate recovery. It is truly amazing that elderly animals were able to make such dramatic physiological improvements.


NMN is found in certain foods and effectively stimulates NAD+ metabolism, a coenzyme the mitochondria depend on to fuel all basic functions within cells. (3,4)

One function of NAD+ is to facilitate communication between the cell nucleus and the mitochondria that power all activity in our cells. (5,6,7)

In previous studies, scientists confirmed a direct link between falling NAD+ levels and aging in both animal and in human subjects and are learning that NAD+ precursors — NMN and NR — can restore NAD+ levels to prevent and even reverse aspects of aging.


This is not the first time NMN made headlines in anti-aging circles. The lead author for this study, Dr. David Sinclair, published research in 2013 that demonstrating:


Raising NAD+ levels in old mice restores mitochondrial function and homeostasis to that of young mice

Key biochemical markers of muscle health in 22-month-old mice returned to levels similar to 6-month-old mice


The 2013 study prompted more research on the benefits and safety of NMN, including this 2016 study, in which mice were treated with NMN for 12 months. The results showed:

NMN was able to mitigate most age-associated physiological decline in mice

Treatment of old mice with NMN reversed all of the biochemical aspects of aging

In a paper published in Science in 2017, Dr. Sinclair identified that the metabolite NAD+, which is naturally present in every cell of our body, has a key role as a regulator in protein-to-protein interactions that control DNA repair. Treating old mice with NMN improved their cells’ ability to repair DNA.


The potential of NMN has been known for over 5 years now, but this most recent study stands out because it:

  1. Shows NEW growth (Angiogenesis) of blood vessels in OLD animals, which is very different than improvement in some metabolic markers that may be temporary.
  2. Is the first time we have seen such a significant improvement in physical performance that actually allowed very old animals to perform as they did when young.
  3. Renewed capillary growth and increased blood flow “reversed vascular aging” and may help reverse heart and neurological problems in addition to sarcopenia.

Remember, as we age, our arteries harden and atrophy resulting in decreased endurance and muscle loss.

Here, the process was not just halted, but REVERSED, with new growth. The number and density of capillaries was the same as in young animals. This is not a temporary phenomenon that might disappear as the body adjusts and homeostasis kicks in.

According to Dr. Sinclair, the same mechanism could also spur the creation of blood vessels in the brain, where “the lack of oxygen and buildup of waste products” (resulting from capillary loss) “sets off a downward spiral of disease and disability” . This may be why studies with NMN and NR have proven effective in early studies of such neurological diseases.

Sinclair and his team are now studying whether increasing NAD+ levels will also spur the creation of blood vessels in the brain.

“Anything that contributes to muscle health through vascular health is likely to be quite important,” said the Buck Institute’s Verdin, who takes a daily NAD+ precursor.

There is great interest in anything that can improve angiogenesis and treat heart disease. Pharmaceutical companies have spent BILLIONS over the last 10 years testing various products. So far, all have failed. It’s interesting that the FDA insists any such medication must improve exercise performance in patients. It’s easy to see why Dr. Sinclair has plans for gaining approval for NMN as a pharmaceutical drug.


Both NMN and NR boost NAD+ and have overlapping effects in studies. At least four clinical studies with humans given NMN supplements are ongoing or completed but not yet published. There have been three human studies published with NR that show results in humans that are similar to experiments in mice (r,r,r).

A study conducted by Elysium Health in 2017 using their product, Basis (NR + Pterostilbene), found improvements in mobility. 120 individuals aged 60-80 were given 250 mg or 500 mg of Basis daily for eight weeks. Those receiving the larger dose experienced:  “7.8% improvement in chair stand and 7.5% improvement in distance walked.”

I wrote at the time that it is nice, but not overwhelming, especially since we don’t know if this increased mobility is at a plateau or may improve. Now, with these results from Dr. Sinclair’s latest research in mice over two months old, we see increased endurance on a much larger scale.

However, the improved capillary growth and blood flow behind the increased endurance would not occur quickly. Two months is a long time to a mouse that live around three years.

As humans live 30-40 times longer than mice, two months in mice time is like six years or so in humans.

We are awaiting results that show NMN works the same in humans, but we do have research that makes it plausible NMN could restore blood flow and physical performance as it does with mice.

Completed or in process human studies with NMN:



MIB-626 is a proprietary, crystallized precursor of NAD+  developed by Metro International Biotech and used in this research.

Metro International Biotech has conducted multiple IRB-approved human safety and bioavailability trials at a prominent Boston hospital, which demonstrated MIB-626 is well tolerated in healthy human volunteer subjects and raises blood levels of NAD+ and related metabolites.



FA is an autosomal recessive inherited mitochondrial disease caused by mutation in the frataxin-encoding gene, which results in loss of coordination, fatigue, muscle loss, vision impairment, hearing loss, slurred speech, cardiomyopathy, diabetes and substantially reduced life expectancy. 1 in 50,000 people are affected and there are currently no disease-modifying therapies available.

Metro International Biotech intends to file an IND in mid-2019 for Phase 2 trials in Frederich’s Ataxia.


Mitochondrial myopathy is a set of mitochondrial diseases that cause progressive muscle weakness and exercise intolerance, due to electron transport chain defects in muscle fibers. Frequently, this manifests as progressive external ophthalmoplegia (PEO), a weakening of the muscles controlling eye movements, which has been slowed by NAD+ repletion in mouse models.

Metro International Biotech intends to file an IND in mid-2019 for Phase 2 trials in mitochondrial myopathy.



Neovascularization—the formation of new blood vessels—should be treated with caution, the researchers say, because increased blood supply could inadvertently fuel tumor growth.

“The last thing you want to do is provide extra blood and nourishment to a tumor if you already have one,” said study co-author Lindsay Wu, at the University of New South Wales School of Medical Sciences.

Sinclair and Wu point out that experiments done provide no evidence treatment with NMN stimulated tumor development in animals treated with the compound.


We do not believe the best answer is large dosages of oral supplements (capsules), but rather taking Sublingual NMN, as it is a more direct route to the blood and avoids the “first pass” metabolism (stomach, intestines, liver) that degrade a very large percentage of NMN and NR supplements.

From studies on sublingual absorption rates on other molecules, we are convinced sublingual NMN is much more effective, but it is difficult to assign a percentage to how much more.

There is no data on how much more effective NMN is in sublingual form. It’s also difficult to study sublingual absorption with mice as they don’t cooperate when trying to put substances under their tongue. 🙂

<!–– the problem with capsules ––>

[post-content id=72706]

<!–– NMN bioavailibity ––>

[post-content id=72710]

<!–– when to take sublingual NMN ? ––>

[post-content id=72698]


According to Dr Wu:
“If these findings translate from mouse to human, we could have a revolutionary impact on the quality of life of older people, and not to mention the benefits of avoiding diseases of aging.”

“This new study adds to the body of work showing that the restoration of NAD+ in mammals can delay and reverse many of the effects of aging.”

Even Dr. Sinclair takes NMN to boost NAD+ levels. “In someone my age [49], it’s probably harder to see immediate benefits,” he said, though he said he feels sharper and younger from it. After his 78-year-old father began taking NMN, “he started climbing mountains and going whitewater rafting and looking forward to the next five years.”

There have been numerous studies documenting improvements from NMN and NR for a wide range of age-related issues, but this is the FIRST evidence that shows actual NEW GROWTH in OLD ANIMALS. NMN enabled them to perform as they did when young.

We are excited about the massive benefits this could bring to hundreds of millions of people. NMN is available now in sublingual tablets, and in powder form, which is perfect for what we believe is the more effective sublingual delivery method.


$38.95 Available on 02/11/2022.
$144.95 Available on 01/31/2022.
These products do not contain NMN or NAD+. They are designed to maximize NAD+ levels by stimulating internal AMPK production (NAD+/AMPD ACTIVATOR), minimize excessive NAD+ consumption from chronic inflammation (NAD+ DEFENDER), or increase H2S and Nitric Oxide levels in the bloodstream (NAD+ ENERGIZER)

Leave a Reply

Your email address will not be published.